Grade Post Therapy Clin (yc)
This input is used for staging
Notes
**Note 1:** Leave Grade Post Therapy Clin (yc) blank when * No neoadjuvant therapy * Clinical or pathological case only * Neoadjuvant therapy completed, no microscopic exam is done prior to surgery/resection of primary tumor * There is only one grade available and it cannot be determined if it is clinical, pathological, post therapy clinical or post therapy pathological **Note 2:** Assign the highest grade from the microscopically sampled specimen of the primary site following neoadjuvant therapy or primary systemic/radiation therapy. **Note 3:** If there are multiple tumors with different grades abstracted as one primary, code the highest grade. **Note 4:** Priority order for codes * Invasive cancers: codes 1-3 take priority over A-D. * In situ cancers: codes L, M, H take priority over A-D **Note 5:** Scarff-Bloom-Richardson (SBR) score is used for grade. SBR is also referred to as: Bloom-Richardson, Nottingham, Nottingham modification of Bloom-Richardson score, Nottingham modification, Nottingham-Tenovus grade, or Nottingham score. **Note 6:** All invasive breast carcinomas should be assigned a histologic grade. The Nottingham combined histologic grade (Nottingham modification of the SBR grading system) is recommended. The grade for a tumor is determined by assessing morphologic features (tubule formation, nuclear pleomorphism, and mitotic count), assigning a value from 1 (favorable) to 3 (unfavorable) for each feature, and totaling the scores for all three categories. A combined score of 3–5 points is designated as grade 1; a combined score of 6–7 points is grade 2; a combined score of 8–9 points is grade 3. * Do not calculate the score unless all three components are available **Note 7:** Grade from nodal tissue may be used **ONLY** when there was **never** any evidence of primary tumor (T0). Grade would be coded using G1, G2, or G3, even if the grading is not strictly Nottingham, which is difficult to perform in nodal tissue. Some of the terminology may include differentiation terms without some of the morphologic features used in Nottingham (e.g., well differentiated (G1), moderately differentiated (G2), or poorly/undifferentiated (G3)). * *Example:* No breast tumor identified, but 2/3 axillary nodes were positive. Determined to be regional node metastasis from breast primary. Nodes were described as poorly differentiated with a high mitotic rate - Code G3 based on the poorly differentiated (which is a high grade) although the terminology used is for nuclear grading **Note 8:** Code 9 (unknown) when * Microscopic exam is done after neoadjuvant therapy and grade from the primary site is not documented * Microscopic exam is done after neoadjuvant therapy and there is no residual cancer * Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available **Note 9:** If you are assigning an AJCC Staging System stage group * Grade is required to assign stage group * Codes A-D are treated as an unknown grade when assigning AJCC stage group * An unknown grade may result in an unknown stage groupNAACCR Item
NAACCR #1068Metadata
SSDI| Code | Description |
|---|---|
| 1 | G1: Low combined histologic grade (favorable), SBR score of 3-5 points Stated as Nottingham/Scarff Bloom-Richardson Grade 1 |
| 2 | G2: Intermediate combined histologic grade (moderately favorable); SBR score of 6-7 points Stated as Nottingham/Scarff Bloom-Richardson Grade 2 |
| 3 | G3: High combined histologic grade (unfavorable); SBR score of 8-9 points Stated as Nottingham/Scarff Bloom-Richardson Grade 3 |
| L | Nuclear Grade I (Low) (in situ only) |
| M | Nuclear Grade II (interMediate) (in situ only) |
| H | Nuclear Grade III (High) (in situ only) |
| A | Well differentiated |
| B | Moderately differentiated |
| C | Poorly differentiated |
| D | Undifferentiated, anaplastic |
| 9 | Grade cannot be assessed (GX); Unknown |
| <BLANK> | See Note 1 |